# Junta clínica — PT-pseudo_4a2fa7bc3595 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_4a2fa7bc3595",
  "pid": "PT-pseudo_4a2fa7bc3595",
  "task": 1,
  "psa": 6.9,
  "age": 67,
  "months": 3,
  "pirads": "5",
  "psad": 0.257,
  "psav": -0.62,
  "psap": 5.6,
  "vol": 26.9,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.84531116,
  "medhx": "Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "metformin, empagliflozin, paracetamol PRN",
  "notes": "PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.",
  "pmhx": [
    "Type 2 diabetes",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "172 cm",
    "bmi": "23.7",
    "bp": "106/78 mmHg",
    "hr": "71 bpm",
    "smoking": "Ex-smoker (16 pack-yr, quit 2006)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels."
    },
    {
      "s": "History",
      "t": "At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement."
    }
  ],
  "occupation": "retired electrical engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Sleep clinic — suspected obstructive sleep apnoea"
  ],
  "alcohol": "3 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4a2fa7bc3595
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.257 ng/mL²
  - PSA velocity: -0.62 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 26.9 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84531116 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.

Vitals: weight 70 kg, height 172 cm, BMI 23.7, BP 106/78 mmHg, HR 71 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2006).

Chief complaint: Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels.

History: At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities.

Physical examination: DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement.

Patient info: retired electrical engineer; Married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 3 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Sleep clinic — suspected obstructive sleep apnoea.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.15 epistemic (95% band 0.34-0.92); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 6.9, PSAD 0.257, age 67, DRE Nodus -> BIOPSY (uncertain). He wrote: "What was the result of the earlier positive biopsy and the MRI precluding that biopsy? Hard to determine what we are looking at here."
  2. distance 0.49: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"
  3. distance 0.60: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: comorbidity=important, pirads=important, psad=important, age=noted, bx=important, vol=important, psa=important, dre=important, cspca=important.
HOW SURE HE USUALLY IS: uncertain.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy is mandated when there is a suspicion of histological progression on MRI. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." This requires establishing if the current MRI findings indicate progression that necessitates a repeat biopsy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled because the guideline requires evidence of histological progression on MRI, which is not established by the panel variables alone. The cohort criterion correctly identifies that the prior positive biopsy means the decision hinges on the documented grade of that prior biopsy and surveillance history, which is not resolved by the panel rules.

WHAT WE STILL NEED
The guideline requires information on the documented grade of the prior biopsy and the number and dates of biopsy sessions in the notes to decide.
Prior biopsy status is documented as "Positive" on the panel, but the specific Gleason or ISUP grade is not provided.
The number and dates of biopsy sessions are not provided, which is required to assess the surveillance history.
The panel shows a csPCa predicted probability of 0.84531116, but the guideline does not provide a threshold for this value to mandate a biopsy in this context.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the documented grade and surveillance history from the previous notes to determine if a repeat biopsy is mandated by the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI prose indicate histological progression that mandates a repeat biopsy?
  psa_trend (get_psa_trend) -> Does the PSA trend indicate progression that mandates a repeat biopsy?
  previous_notes (get_previous_notes) -> What is the documented grade (Gleason/ISUP) of the prior biopsy and the surveillance history?
  laboratory_results (get_lab_results) -> Does the full lab panel provide any information relevant to the need for a repeat biopsy?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What was the result of the earlier positive biopsy, specifically the Gleason or ISUP grade?
  Q2. What is the number and dates of previous biopsy sessions, and is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose indicates a PI-RADS 5 lesion in the right peripheral zone with rapid, robust enhancement.
psa_trend
The PSA trend shows a rise from "2.3" ng/mL on "Apr 2023" to "6.9" ng/mL on "Feb 2025".
previous_notes
The documented grade of the prior biopsy is not provided, and the surveillance history is not explicitly detailed beyond noting a consultation after the first positive biopsy.
laboratory_results
The full lab panel shows a PSA of "6.9 ng/mL" on "18 Jan 2025".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already addressed the relevant history context.

WHAT THIS SUPPORTS
FOR sampling this patient now:
The mpMRI report shows a PI-RADS 5 lesion with rapid, robust enhancement.
The PSA trend shows a clear upward trajectory from 2.3 ng/mL to 6.9 ng/mL.

AGAINST sampling this patient now:
The previous notes do not document the specific Gleason or ISUP grade of the prior biopsy.
The previous notes do not explicitly detail the number and dates of previous biopsy sessions or current surveillance protocol status.

WHERE THIS LEANS
The findings suggest a need for further clarification regarding the prior biopsy result and surveillance status before a definitive decision can be made.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.90 ng/mL over 3 points spanning 22 months; velocity +2.51 ng/mL per year; doubling time about 14 months.
PROJECTION at 6 months: 10.3 ng/mL, conformal 95% band 2.9-35.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.70
  uncertainty  +/- 0.14 epistemic (95% band 0.44-0.97), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.70  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.86  (identical panel in the series)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: uncertain. Weights it expects: comorbidity=important, pirads=important, psad=important, age=noted, bx=important, vol=important, psa=important, dre=important, cspca=important.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, previous_notes, and laboratory_results—do not fully answer the moderator's questions. Specifically, the previous_notes do not document the specific Gleason or ISUP grade of the prior biopsy, nor do they explicitly detail the number and dates of previous biopsy sessions or current surveillance protocol status.

ALIGNMENT WITH THE PANEL
The PANEL-PROTOCOL concludes BIOPSY based on an identical precedent in the labelled series (EXPERT-LIBRARY). However, this conclusion rests on the finding that "documented prior grade in the opened documents: none recorded," which directly relates to the missing information required by the EAU guideline.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What was the result of the earlier positive biopsy, specifically the Gleason or ISUP grade? This question remains unanswered as the previous_notes do not provide this specific histological grade.
Q2. What is the number and dates of previous biopsy sessions, and is the patient currently on a surveillance protocol with a confirmatory biopsy due? This question remains unanswered as the previous_notes do not explicitly detail the surveillance history.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the documented prior biopsy result (Gleason/ISUP grade) and the surveillance history. These are critical because the EAU guideline explicitly mandates a repeat biopsy based on evidence of histological progression, which requires knowing the prior grade and surveillance status.

MY SUGGESTION TO THE CHAIR
Given that the required information regarding the prior biopsy grade and surveillance history is missing from the retrieved documents, the record is not yet in a state to be decided according to the guideline. Therefore, the decision cannot be made yet.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: uncertain)

A repeat biopsy is indicated because the MRI showed a PI-RADS 5 lesion with rapid, robust enhancement, and the PSA trend demonstrated a clear upward trajectory from 2.3 ng/mL to 6.9 ng/mL. Although the specific prior biopsy grade was not documented, the convergence of the evidence, particularly the high-risk imaging features and rising PSA, settled the decision to proceed with a biopsy.

What carried weight: comorbidity=important, pirads=important, psad=important, age=noted, bx=important, vol=important, psa=important, dre=important, cspca=important
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
